Drug Shortage Report for EMGALITY
| Report ID | 173230 |
| Drug Identification Number | 02505134 |
| Brand name | EMGALITY |
| Common or Proper name | galcanezumab injection |
| Company Name | ELI LILLY CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | GALCANEZUMAB |
| Strength(s) | 100MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Packaging size | Carton package containing three 100 mg/mL prefilled syringes |
| ATC code | N02CD |
| ATC description | |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-10-27 |
| Estimated end date | 2023-01-16 |
| Actual end date | 2023-01-16 |
| Shortage status | Resolved |
| Updated date | 2023-01-17 |
| Company comments | For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
| Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2023-01-17 | English | Compare |
| v4 | 2023-01-16 | French | Compare |
| v3 | 2023-01-16 | English | Compare |
| v2 | 2022-11-01 | French | Compare |
| v1 | 2022-11-01 | English | Compare |
Showing 1 to 5 of 5